Estriol is a type of estrogen, a hormone that helps with pregnancy. It's mainly made by the placenta during pregnancy. It's also found in urine, so it's sometimes called a urinary estrogen.
Every report comes from a Lived member, sent anonymously.
Have you tried Estriol for Vaginal Thinning?
Estriol is one of the body's three main estrogens, the female sex hormones. It is much weaker than estradiol, the main estrogen before menopause, and is made mostly by the placenta during pregnancy. As a medicine, it is used mainly in low doses inside the vagina to treat vaginal atrophy after menopause: the thinning, drying and loss of elasticity of vaginal and vulvar tissue that follows the drop in estrogen. This can cause dryness, itching, burning and pain during sex, and is part of what doctors call genitourinary syndrome of menopause (GSM). In Europe, vaginal estriol is the estrogen most often chosen for these symptoms. It is sold as a cream, vaginal tablets or pessaries (small inserts) and gels, under brand names such as Ovestin in Australia and Ovesse in the UK, and as generic estriol products. Some countries also sell estriol tablets taken by mouth. Urology guidelines also recommend vaginal estrogen to help prevent repeated bladder infections after menopause, and one of the best-known trials of this used estriol cream, although no product's label lists that use. In the US, no estriol medicine is approved by the FDA. Estriol prescribed there is made by compounding pharmacies, either alone or blended with estradiol in mixtures often called Bi-est (commonly 80% estriol and 20% estradiol) or Tri-est, and is often promoted as a bioidentical hormone. These preparations are not reviewed by the FDA, their strength and absorption can vary between batches and pharmacies, and a 2020 National Academies review found too little evidence to say whether compounded estriol is as safe or effective as approved hormone products. FDA-approved vaginal estrogens, such as estradiol vaginal tablets (Vagifem) or the estradiol vaginal ring (Estring), are the usual US alternatives.
Estrogen keeps the lining of the vagina thick, moist and elastic, and supports lactobacilli, the protective bacteria that keep the vagina mildly acidic. After menopause, as estrogen falls, the lining thins and the bacterial balance shifts, which leads to dryness and irritation and makes urinary infections more likely. Estriol placed in the vagina acts on estrogen receptors in that tissue, helping the lining rebuild and restoring the normal bacteria and acidity. Estriol binds estrogen receptors less strongly than estradiol and is short-acting. With vaginal use at standard doses, blood levels rise briefly after each dose and then fall back, and studies have not found lasting changes in other hormone levels. This is why licensed low-dose vaginal estriol is used without a progestogen, the hormone usually added to estrogen to protect the womb lining. Taken by mouth, estriol acts throughout the body, so that reassurance does not carry over to tablets or to higher-dose compounded creams.
Vaginal estriol cream comes with a reusable applicator marked to measure one dose. A typical licensed regimen, such as Ovesse in the UK, starts with one applicator dose (0.5 mg of estriol) every day for two weeks, then continues with one application twice a week. Many people apply it at bedtime. Pessaries and gels follow a similar pattern of daily use at the start and then two or three times a week, but strengths differ between products, so follow the instructions for the specific one prescribed. If a dose is missed, use it when remembered, but not two doses on the same day. Using more, or more often, than prescribed increases the estrogen reaching the womb lining without improving relief. Compounded US preparations have no standard dose; the strength depends on the individual prescription and the pharmacy that makes it.
The most common side effects are local: irritation, itching or a burning feeling in or around the vagina, especially in the first weeks. Some people notice breast tenderness, more vaginal discharge, nausea or headache. These are usually temporary, but if they persist they can be a sign the dose is higher than needed. The cream base can occasionally cause a skin reaction such as contact dermatitis. Any vaginal bleeding or spotting during treatment should be reported to the prescriber rather than assumed to be a side effect. After menopause, bleeding needs to be checked for its cause, which sometimes includes taking a sample of the womb lining.
Because so little is absorbed from vaginal doses, important drug interactions are not expected. The prescriber should still know about any other hormone treatment, including menopausal hormone therapy, and about other vaginal products used at the same time. Product labels list reasons not to use estriol: a current, past or suspected estrogen-sensitive cancer, such as breast, ovarian or endometrial (womb lining) cancer; vaginal bleeding that has not been explained; a current or past blood clot in a vein or the lungs, or an inherited clotting disorder; a recent heart attack or stroke; and active liver disease. For someone with a history of breast cancer, any vaginal estrogen is a decision to make with the cancer care team. Estriol is not used during pregnancy or breastfeeding. The risks known from whole-body hormone therapy, such as blood clots and stroke, apply to a much lesser extent to low-dose vaginal estriol, but they are not ignored. Painful swelling in one leg needs prompt medical advice, and sudden chest pain or sudden shortness of breath needs emergency care, because these can signal a blood clot. Long-term estriol taken by mouth was linked in one study to a higher risk of endometrial cancer, which was not seen with vaginal use, so tablets and higher-dose compounded products call for the same precautions as other estrogen therapy.
Relief of dryness and irritation often begins within the first few weeks of treatment. If symptoms have not started to improve, or have worsened, after about three months, the diagnosis and treatment should be reviewed rather than the dose simply increased. Vaginal atrophy reflects a lasting drop in estrogen, so symptoms often come back when treatment stops. Many people continue at the twice-weekly maintenance dose for as long as it helps, with a review at least once a year. After a break, treatment is usually restarted at the maintenance dose, or at the daily starting dose for two weeks if symptoms have fully returned.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Estriol, what you've noticed, or ask the community a question.